A Phase 3 interventional study of PA21 in Peritoneal Dialysis and Hyperphosphatemia, sponsored by Kissei Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-11-13.
Sponsored by Kissei Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment
The purpose of this study is to investigate efficacy and safety, when administering PA21, in peritoneal dialysis patients having hyperphosphatemia.
148 studies on the registry are indexed under Hyperphosphatemia; 10 are open to participants now.
Browse Hyperphosphatemia studies →Kissei Pharmaceutical Co., Ltd. is the lead sponsor of 61 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: PA21
Serum phosphate concentrations
Time frame: 12 weeks
Incidences of Adverse Events
Time frame: 12 weeks
Incidences of Adverse Events
Time frame: 28 weeks
Serum phosphate concentrations
Time frame: 28 weeks
This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kissei Pharmaceutical Co., Ltd.